Abliva: Potentially faster to market
Research Note
2020-09-11
12:49
Redeye maintains its fair value of Abliva at SEK 1.4 per share. Optimism around its main asset, KL1333, has increased, but there are still many unknowns concerning clinical outcomes and financing.
GA
Gergana Almquist
Disclosures and disclaimers